icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
Ledipasvir/Sofosbuvir + Ribavirin for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-World Dataset
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
M Charlton1, MCM Cheung2, M Manns3, N Sajed4, PJF Troke5, J Spellman4, A Copans4, S Arterburn4, DM Brainard4, WL Irving6, HCV Research UK, GR Foster2 1Division of Hepatology and Liver Transplantation, Intermountain Medical Center, Salt Lake City, Utah; 2Liver Unit, Blizard Institute, Queen Mary University of London, London, United Kingdom; 3Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, and German Center of Infection Research (DZIF), Hannover-Braunschweig, Germany; 4Gilead Sciences, Inc., Foster City, California; 5Gilead Sciences Ltd, London, United Kingdom; 6NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham, United Kingdom

HCV1

HCV2

HCV3

HCV4

HCV5

HCV6

HCV7